A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

Summary

The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.

Timeline

Start

2024-06-27

Primary completion

2027-06

Completion

2027-12

Drugs

Indications